Research Nester published a report titled “CAR T-Cell Therapy Market: Global Demand Analysis Opportunity Outlook 2030” which delivers detailed overview of the global CAR T-cell therapy market in terms of market segmentation by targeted antigen, therapeutic application, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global CAR T-cell therapy market is estimated to occupy a large amount of revenue by growing at a CAGR of 38.7% during the forecast period, i.e., 2022 – 2030, owing to the growing occurrence of cancer across the globe, and rising technological advancements to develop improved treatment for cancer. Along with these, increasing number of cell therapy-based clinical studies, and growth of the pharmaceutical industry in developed and developing nations are also expected to significantly drive market growth in the forthcoming years.

The market is segmented by targeted antigen and therapeutic application. Based on targeted antigen, the CD19 segment is anticipated to occupy the largest share during the forecast period on the back of the high efficacy of this antigen in cancer therapy as it is expressed only in B lineage cells, such as those causing malignancies such as leukemia and lymphoma. Additionally, by therapeutic application, the diffuse large B-cell lymphoma segment is projected to grab the largest share over the forecast period attributing to the rising prevalence of this disease globally, especially in the United States.

Geographically, the global CAR T-cell therapy market is segmented into five major regions, namely North America, Europe, Latin America, Asia Pacific, and the Middle East Africa. North America region is evaluated to grab the largest share in the market during the forecast period attributing to the high healthcare expenditure, and strong presence of major market players in the region. Moreover, the market in Asia Pacific is assessed to grow by a noteworthy rate in the future owing to the escalating number of cancer cases in China and India, and surging geographical expansion by market players in the region.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Increasing Prevalence of Cancer Around the World to Drive Market Growth

As per a report by the World Health Organization’s Global Cancer Observatory (GLOBOCAN), in 2020, breast and lung cancers were the two most common cancers worldwide, with 2.26 million and 2.21 million people affected by both the diseases respectively.

With the upsurge in the total incidences of cancer, the world is witnessing the need for more advanced therapies for the disease. In addition, some cancers, including myeloma and monocytic leukemia, are incurable. CAR T-cell therapy consolidates remission and aims towards a cure for illnesses like these. This in turn is predicted to bolster market growth significantly in the near future.

However, expensiveness of CAR T-cell therapy, and its adverse side effects are expected to operate as key restraint to the growth of the global CAR T-cell therapy market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global CAR T-cell therapy market which includes company profiling of bluebird bio, Inc., Noile-Immune Biotech, Celgene Corporation, Bellicum Pharmaceuticals, Inc., Novartis International AG, Servier Canada Inc., Pfizer, Inc., Caribou Biosciences, Inc., Merck KGaA, Amgen Inc, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global CAR T-cell therapy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.     

Request Report Sample@ https://www.researchnester.com/sample-request-3750

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919